Fairmount Funds Management’s Zenas BioPharma ZBIO Stock Holding History

Fairmount Funds Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$46.1M	Buy	2,359,025 +150,000	+7%	+$3.37M	3.33%	10
2025 Q4	$80.2M	Buy	2,209,025 +316,219	+17%	+$10.4M	6.11%	7
2025 Q3	$42M	Hold	1,892,806	–	–	3.78%	13
2025 Q2	$18.3M	Hold	1,892,806	–	–	2.38%	15
2025 Q1	$15M	Hold	1,892,806	–	–	2.32%	13
2024 Q4	$15.5M	Hold	1,892,806	–	–	1.54%	17
2024 Q3	$32M	Buy	+1,892,806	New	+$34M	2.6%	14

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fairmount Funds Management's ZBIO Position: Q1 2026 in Review

Fairmount Funds Management increased its Zenas BioPharma (ZBIO) stake by 6.8% in Q1 2026, buying an estimated $3.37M and bringing the position to 2,359,025 shares worth $46.1M. The position accounts for 3.33% of the portfolio, ranked #10.

Fairmount Funds Management first reported a position in ZBIO in Q3 2024 and has held it in 7 quarters since. The position peaked at $80.2M in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

Fairmount Funds Management held 2,359,025 shares of Zenas BioPharma worth $46.1M as of Q1 2026.
Fairmount Funds Management bought 150,000 Zenas BioPharma shares in Q1 2026, an estimated $3.37M.
Zenas BioPharma made up 3.33% of Fairmount Funds Management's portfolio in Q1 2026, its #10 holding.
Fairmount Funds Management first reported a position in Zenas BioPharma in Q3 2024 and has held it in 7 quarters since.
Fairmount Funds Management's Zenas BioPharma position peaked at $80.2M in Q4 2025.
139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Fairmount Funds Management's 13F filing for Q1 2026, filed 15 May 2026.